New approaches in treatment of gout: febuxostat


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Обсуждается эффективность и безопасность нового непуринового производного ингибитора ксантиноксидазы - фебуксостата. Приводятся результаты фармакокинетических исследований, сравнительных с аллопуринолом клинических исследований препарата на больных, страдающих подагрой и/или гиперурикемией, а также его взаимодействие с другими лекарственными средствами. Представлены особенности действия фебуксостата на пациентов с почечной и печеночной недостаточностью и основные побочные эффекты.

Негізгі сөздер

Толық мәтін

Рұқсат жабық

Әдебиет тізімі

  1. Garcia-Valladares I., Khan T., Espinoza L.R. Efficacy and safety of febuxostat in patients with hyperuricemia and gout. Ther. Adv. Musculoskelet. Dis. 2011; 3 (5): 245-253.
  2. Emmerson B.T. The management of gout. N. Eng. J. Med. 1996; 334: 445451.
  3. Fox I.H., Kelley W.N. Management of gout. JAMA. 1979; 242: 361-364.
  4. Chen L.X., Schumacher H.R. Febuxostat treatment for gout: what the clinician needs to know. Ther. Adv. Musculoskel. Dis. 2009; 1(2): 67-69.
  5. Gaffo A.L., Saag K.G. Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout. Core Evidence. 2009; 4: 25-36.
  6. Takano Y., Hase-Aoki K., Horiuchi H. et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 2005; 76:1835-1847.
  7. Sanches-Lozada L.G., Tapia E., Bautista-Garsia P. et al. Effect of febuxostat on metabolic and renal alteration in rat with fructose-induced metabolic syndrome. Am. J. Physiol. Renal. Physiol. 2008; 294: 710-718.
  8. Zhao L. et al. цит. по Hu M. и Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther. Clin. Risk Manag. 2008; 4 (6): 1209-1220.
  9. Becker M.A., Schumacher H. R., Wortmann R.L. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Eng. J. Med. 2005; 353: 2450-2461.
  10. Khosravan R., Kukulka M.J., Wu J.T. et al. The effect of age and gender on pharmacokinetics, pharmacodynamics and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J. Clin. Pharmacol. 2008; 48: 1014-1024.
  11. Mayer M.D., Khosravan R., Vernillet L. et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am. J. Ther. 2005; 1: 22-34.
  12. Khosravan R., Grabowsky B.A., Wu J.T. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in health subjects. Clin. Pharmacokinet. 2006; 45: 821-841.
  13. Khosravan R., Grabowski B., Wu J-T. et al. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in health subjects. Br. J. Clin. Pharmacol. 2008; 65 (3): 355-363.
  14. Khosravan R., Wu J.T., Joseph-Ridge N., Vernillet L. Pharmacokinetic interaction of concomitant administration of febuxostat and NSAIDs. J. Clin. Pharmacol. 2006; 46: 855-866.
  15. Grabowski B., Khosravan R., Wu J.T. et al. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a nonpurine selective inhibitor of xanthine oxidase. Br. J. Clin. Pharmacol. 2010; 70 (1): 57-64.
  16. Hoshide S. et al. цит. по Hu M., Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther and Clin Risk Management. 2008; 4 (6): 1209-1220.
  17. Khosravan R., Grabowski B.A., Mayer M.D. et al. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics and safety of febuxostat, a novel non-purine selective inhibitor of xantin oxidase. J. Clin. Pharmacol. 2006; 46: 88-102.
  18. Whelton A., MacDonald P.A., Zhao L. et al. Renal function in gout: long-term treatment effects of febuxostat. J. Clin. Rheumatol. 2011; 17: 7-13.
  19. Becker M.A., Schumacher H. R., Wortmann R.L. et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trials examining safety and efficacy in patients with gout. Arthritis Rheum. 2005; 52 (3): 916-923.
  20. Becker M.A., Schumacher H. R., Wortmann R.L. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J Med. 2005; 353: 2450-2461.
  21. Schumacher H.R., Becker M.A., Wortmann R.L. et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008; 59: 1540-1548.
  22. Becker M. et al. цит по Gaffo A.L., Saag K.G. Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout. Core Evidence. 2009; 4: 25-36.
  23. Becker M.A., Schumacher H.R., Espinoza L.R. et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research and Therapy. 2010; 12 (2): R63.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>